Arcturus Therapeutics Holdings Inc. (ARCT), a commercial mRNA medicines and vaccines company, has a clinical trial catalyst to watch next week.
The company is scheduled to report interim data from its phase II trials of its investigational therapy ARCT-810 in participants with Ornithine Transcarbamylase (OTC) deficiency on June 30, 2025.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com